<DOC>
	<DOCNO>NCT01315431</DOCNO>
	<brief_summary>This study perform confirm safety tesetaxel 27 mg/m2 ( Day 1 ) combination capecitabine 2000/mg/m2/day ( 2 equally divided dos Days 1 14 ) 21-day cycle .</brief_summary>
	<brief_title>A Study Tesetaxel Plus Capecitabine Patients With Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Capecitabine</mesh_term>
	<criteria>At least 18 year age Confirmed diagnosis solid tumor malignancy , exclude lymphoma Chemotherapyna√Øve previously treat 1 nontaxanecontaining chemotherapy ( Enrollment patient history prior taxane therapy adjuvant set allow provide least 6 month pass since conclusion therapy . ) ECOG performance status 0 1 Adequate bone marrow , hepatic , renal function At least 3 week recovery effect prior surgery anticancer therapy , resolution toxicity Grade 1 Brain metastasis leptomeningeal disease Second cancer ( except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , cancer patient diseasefree 5 year ) Known history human immunodeficiency virus infection hepatitis B hepatitis C infection Recurrent diarrhea , define 3 episode usual 24hour period within 30 day prior enrollment study Significant medical disease cancer Neuropathy least Grade 2 Difficulty swallow Malabsorptive disorder Need anticancer treatment receive study medication Need continue regularlytaken medication potent inhibitor inducer CYP3A pathway Pglycoprotein activity . A washout period least 2 week require prior first dose study medication . Pregnancy lactation History hypersensitivity tesetaxel , capecitabine , 5fluorouracil , component</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Solid tumor malignancy , exclude lymphoma</keyword>
</DOC>